RxDoctor Payments Data

Natalie Stewart, NP

Nurse Practitioner · Rome, GANPI 1184983124

Payments from drug & device makers

$858in general payments, 2019–2025

Across 31 payments — averaging $27.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ferring Pharmaceuticals Inc.$216
  • Astellas Pharma US Inc$170
  • Sumitomo Pharma America, Inc.$119
  • 180 Medical, Inc.$66
  • Axonics, Inc.$60
  • Coloplast$53
  • plus $174 from 6 others

What the payments were for

  • Speaking & faculty fees$11914%
  • Food & beverage$64976%
  • Education$9010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$858 in reported general payments places this provider in the 70th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$99,568
Medicare patients
378
Services billed
3,457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron148$117,793
GemtesaVibegron76$49,483
Tamsulosin Hcl416$6,429
Methenamine Hippurate89$5,980
Estradiol62$3,879
Testosterone24$2,610
Finasteride106$1,487
Alfuzosin Hcl ErAlfuzosin Hcl98$1,463
Potassium Citrate ErPotassium Citrate11$1,319
Oxybutynin Chloride ErOxybutynin Chloride18$825
Trospium Chloride13$823
Silodosin12$793
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst49$730
Cefdinir48$684
Testosterone Cypionate17$659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$170$117,793148 claims
Sumitomo Pharma America, Inc.Gemtesa$119$49,48376 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →